Personalized mRNA Cancer Vaccine Cuts Melanoma Recurrence by 42%

· Health · United States

Results from the phase 3 INTerpath-001 trial, presented at the ESMO Congress 2026, show that adding the personalized mRNA-based cancer vaccine intismeran autogene to pembrolizumab after surgery for high-risk melanoma reduced the risk of recurrence or death by 42%. The vaccine is being developed by Moderna with Merck. The data drew heavy attention at the Madrid meeting and, according to BioPharma Dive, sparked a share sell-off on Wall Street even as scientists hailed it. Moderna CEO Stephane Bancel said the partners are racing to submit the vaccine for FDA approval, expected in 2027, and the race is widening to additional tumor types. Merck also used the congress to present other oncology pipeline data beyond the vaccine.

Why it matters：A positive phase 3 readout for a personalized neoantigen vaccine would validate an entirely new manufacturing-and-treatment model for oncology, pushing rivals to accelerate their own mRNA and individualized therapy programs.

Key points

  • The 42% reduction covered recurrence or death in high-risk melanoma patients after surgery.
  • The vaccine, intismeran autogene, was given alongside pembrolizumab.
  • FDA submission is expected in 2027, per Moderna's CEO.

Sources (original reporting)

More stories from this day